Adenosine Receptor Subtypes Mediating Coronary Vasodilation in Rat Hearts

Adenosine receptor-mediated coronary vasodilation was studied in isolated hearts from young (1–2 months) and mature (12–18 months) Wistar rats. The nonselective agonist 5´-N-ethylcarboxamidoadenosine (NECA) induced biphasic concentration-dependant dilation with similar potencies in both age groups (...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cardiovascular pharmacology Vol. 41; no. 1; pp. 73 - 80
Main Authors: Hinschen, Andrea K, Rose'Meyer, Roselyn B, Headrick, John P
Format: Journal Article
Language:English
Published: Philadelphia, PA Lippincott Williams & Wilkins, Inc 01-01-2003
Hagerstown, MD Lippincott
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Adenosine receptor-mediated coronary vasodilation was studied in isolated hearts from young (1–2 months) and mature (12–18 months) Wistar rats. The nonselective agonist 5´-N-ethylcarboxamidoadenosine (NECA) induced biphasic concentration-dependant dilation with similar potencies in both age groups (p < 0.05). Despite similar potencies, responses to NECA were significantly depressed by 50% with age. NECA-mediated dilation was unaltered by selective A1 adenosine receptor (A1AR) antagonist 1,3-dipropyl-8-cyclopentylxanthine (DPCPX, 100 n M) or A2A adenosine receptor (A2AAR) antagonist 5-amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (SCH 58261, 100 n M). However, the A2B adenosine receptor (A2B AR) selective antagonist alloxazine (10 μM) significantly reduced response magnitude to NECA in both age groups. Concentration–response curves to N-2-(4-aminophenyl) ethyladenosine (APNEA) induced biphasic concentration-dependent dilation in hearts from young animals. In the presence of the three combined antagonists, 1 μM DPCPX, 100 n M SCH 58261, and 1 μM alloxazine, the response magnitude was significantly attenuated (p < 0.05). The addition of the A3 adenosine receptor (A3AR) antagonist 3-ethyl-5-benzyl-2-methyl-4-phenylethyl-6-phenyl-1,4-(±)-dihydropyridine-3,5-dicarboxylate (MRS1191, 100 n M) to the combined antagonists further attenuated vasodilator responses to APNEA. The results suggest that multiple adenosine receptor subtypes mediate dilation in the rat coronary circulation. NECA mediates vasodilation via the A2BAR subtype, while dilator responses to APNEA in the presence and absence of A1, A2, and A3 AR antagonists provide evidence for a vasodilator role for A3 ARs in rat coronary circulation. The magnitude of the coronary dilator response is reduced with age and does not involve A2A or A1 ARs.
AbstractList Adenosine receptor-mediated coronary vasodilation was studied in isolated hearts from young (1–2 months) and mature (12–18 months) Wistar rats. The nonselective agonist 5´-N-ethylcarboxamidoadenosine (NECA) induced biphasic concentration-dependant dilation with similar potencies in both age groups (p < 0.05). Despite similar potencies, responses to NECA were significantly depressed by 50% with age. NECA-mediated dilation was unaltered by selective A1 adenosine receptor (A1AR) antagonist 1,3-dipropyl-8-cyclopentylxanthine (DPCPX, 100 n M) or A2A adenosine receptor (A2AAR) antagonist 5-amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (SCH 58261, 100 n M). However, the A2B adenosine receptor (A2B AR) selective antagonist alloxazine (10 μM) significantly reduced response magnitude to NECA in both age groups. Concentration–response curves to N-2-(4-aminophenyl) ethyladenosine (APNEA) induced biphasic concentration-dependent dilation in hearts from young animals. In the presence of the three combined antagonists, 1 μM DPCPX, 100 n M SCH 58261, and 1 μM alloxazine, the response magnitude was significantly attenuated (p < 0.05). The addition of the A3 adenosine receptor (A3AR) antagonist 3-ethyl-5-benzyl-2-methyl-4-phenylethyl-6-phenyl-1,4-(±)-dihydropyridine-3,5-dicarboxylate (MRS1191, 100 n M) to the combined antagonists further attenuated vasodilator responses to APNEA. The results suggest that multiple adenosine receptor subtypes mediate dilation in the rat coronary circulation. NECA mediates vasodilation via the A2BAR subtype, while dilator responses to APNEA in the presence and absence of A1, A2, and A3 AR antagonists provide evidence for a vasodilator role for A3 ARs in rat coronary circulation. The magnitude of the coronary dilator response is reduced with age and does not involve A2A or A1 ARs.
Adenosine receptor-mediated coronary vasodilation was studied in isolated hearts from young (1-2 months) and mature (12-18 months) Wistar rats. The nonselective agonist 5'-N-ethylcarboxamidoadenosine (NECA) induced biphasic concentration-dependant dilation with similar potencies in both age groups (p < 0.05). Despite similar potencies, responses to NECA were significantly depressed by 50% with age. NECA-mediated dilation was unaltered by selective A adenosine receptor (A1AR) antagonist 1,3-dipropyl-8-cyclopentylxanthine (DPCPX, 100 nM ) or A adenosine receptor (A2AAR) antagonist 5-amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5- ]pyrimidine (SCH 58261, 100 nM ). However, the A2B adenosine receptor (A2B AR) selective antagonist alloxazine (10 microM ) significantly reduced response magnitude to NECA in both age groups. Concentration-response curves to N -2-(4-aminophenyl) ethyladenosine (APNEA) induced biphasic concentration-dependent dilation in hearts from young animals. In the presence of the three combined antagonists, 1 microM DPCPX, 100 nM SCH 58261, and 1 microM alloxazine, the response magnitude was significantly attenuated (p < 0.05). The addition of the A3 adenosine receptor (A3AR) antagonist 3-ethyl-5-benzyl-2-methyl-4-phenylethyl-6-phenyl-1,4-(+/-)-dihydropyridine-3,5-dicarboxylate (MRS1191, 100 nM ) to the combined antagonists further attenuated vasodilator responses to APNEA. The results suggest that multiple adenosine receptor subtypes mediate dilation in the rat coronary circulation. NECA mediates vasodilation via the A2BAR subtype, while dilator responses to APNEA in the presence and absence of A1, A2, and A3 ARs antagonists provide evidence for a vasodilator role for A3 ARs in rat coronary circulation. The magnitude of the coronary dilator response is reduced with age and does not involve A2A or A1 ARs.
Adenosine receptor-mediated coronary vasodilation was studied in isolated hearts from young (1-2 months) and mature (12-18 months) Wistar rats. The nonselective agonist 5'-N-ethylcarboxamidoadenosine (NECA) induced biphasic concentration-dependant dilation with similar potencies in both age groups (p &lt; 0.05). Despite similar potencies, responses to NECA were significantly depressed by 50% with age. NECA-mediated dilation was unaltered by selective A adenosine receptor (A1AR) antagonist 1,3-dipropyl-8-cyclopentylxanthine (DPCPX, 100 nM ) or A adenosine receptor (A2AAR) antagonist 5-amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5- ]pyrimidine (SCH 58261, 100 nM ). However, the A2B adenosine receptor (A2B AR) selective antagonist alloxazine (10 microM ) significantly reduced response magnitude to NECA in both age groups. Concentration-response curves to N -2-(4-aminophenyl) ethyladenosine (APNEA) induced biphasic concentration-dependent dilation in hearts from young animals. In the presence of the three combined antagonists, 1 microM DPCPX, 100 nM SCH 58261, and 1 microM alloxazine, the response magnitude was significantly attenuated (p &lt; 0.05). The addition of the A3 adenosine receptor (A3AR) antagonist 3-ethyl-5-benzyl-2-methyl-4-phenylethyl-6-phenyl-1,4-(+/-)-dihydropyridine-3,5-dicarboxylate (MRS1191, 100 nM ) to the combined antagonists further attenuated vasodilator responses to APNEA. The results suggest that multiple adenosine receptor subtypes mediate dilation in the rat coronary circulation. NECA mediates vasodilation via the A2BAR subtype, while dilator responses to APNEA in the presence and absence of A1, A2, and A3 ARs antagonists provide evidence for a vasodilator role for A3 ARs in rat coronary circulation. The magnitude of the coronary dilator response is reduced with age and does not involve A2A or A1 ARs.
Author Headrick, John P
Hinschen, Andrea K
Rose'Meyer, Roselyn B
AuthorAffiliation Heart Foundation Research Center, School of Health Science, Griffith University Gold Coast Campus, Southport, QLD 4215, Australia
AuthorAffiliation_xml – name: Heart Foundation Research Center, School of Health Science, Griffith University Gold Coast Campus, Southport, QLD 4215, Australia
Author_xml – sequence: 1
  givenname: Andrea
  surname: Hinschen
  middlename: K
  fullname: Hinschen, Andrea K
  organization: Heart Foundation Research Center, School of Health Science, Griffith University Gold Coast Campus, Southport, QLD 4215, Australia
– sequence: 2
  givenname: Roselyn
  surname: Rose'Meyer
  middlename: B
  fullname: Rose'Meyer, Roselyn B
– sequence: 3
  givenname: John
  surname: Headrick
  middlename: P
  fullname: Headrick, John P
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14467850$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/12500024$$D View this record in MEDLINE/PubMed
BookMark eNp1kVtPwyAUgImZ0W36Fwwv-laFQil9XBZ1S2ZM5uWVUHrqqh1MaGP89zI39UkSQg75zoWPERpYZwEhTMklJUV-ReLKGOdJSggjNEZJ3JQcoCHNGEs4SdkADQkVJEk5F8doFMJrJHiWiyN0TNMs8ikfovmkAutCYwEvwcCmcx4_9GX3uYGA76BqdNfYFzx13lntP_GzDq5q2njrLG4sXuoOz0D7Lpygw1q3AU735xg93Vw_TmfJ4v52Pp0sEsNZHEfnTEtjSGXKUuhSyoJolpV1WcmcGiGIrEjOeCEyUUDKdVaznBWVKClLTQ2GjdHFru7Gu_ceQqfWTTDQttqC64PKU1lQWRQRlDvQeBeCh1ptfLOOj1CUqK1G9aNR_WpU3xpj6tm-R1-uofpL3HuLwPke0MHotvbamib8cdF5LrNtIb7jPlzbgQ9vbf8BXq1At91K_feN7Aux2osC
CODEN JCPCDT
CitedBy_id crossref_primary_10_1097_SHK_0b013e3181f221fb
crossref_primary_10_1081_CEH_120025332
crossref_primary_10_1002_jcb_21586
crossref_primary_10_1161_CIRCULATIONAHA_110_952481
crossref_primary_10_1007_s11302_014_9436_1
crossref_primary_10_1186_1472_6793_5_10
crossref_primary_10_1016_j_jacc_2008_11_014
crossref_primary_10_1016_j_bbamem_2010_11_016
crossref_primary_10_3109_01480545_2010_495947
crossref_primary_10_4020_jhrs_23_21
crossref_primary_10_1097_FJC_0b013e318201c264
crossref_primary_10_1124_jpet_110_170803
crossref_primary_10_1186_1471_2393_14_2
crossref_primary_10_1016_j_pharmthera_2022_108213
crossref_primary_10_1016_j_jss_2010_02_013
crossref_primary_10_3181_0812_RM_350
crossref_primary_10_1186_s41747_022_00319_4
crossref_primary_10_1093_cvr_cvq371
crossref_primary_10_1152_ajpheart_01319_2005
crossref_primary_10_1016_j_vph_2006_05_005
crossref_primary_10_1021_cb5004042
crossref_primary_10_1016_j_jss_2006_08_019
crossref_primary_10_3389_fphar_2017_00858
crossref_primary_10_1016_j_ejphar_2008_01_044
crossref_primary_10_1016_j_mvr_2009_01_004
crossref_primary_10_1016_j_mam_2017_01_004
crossref_primary_10_1007_s00395_006_0621_4
crossref_primary_10_1016_j_ejphar_2013_01_049
crossref_primary_10_1152_ajpheart_00684_2004
crossref_primary_10_1186_2193_9616_1_24
crossref_primary_10_3390_biomedicines12040876
crossref_primary_10_1016_j_pharmthera_2007_02_004
crossref_primary_10_1016_j_phrs_2013_08_007
crossref_primary_10_1021_jm050726b
crossref_primary_10_1152_ajpheart_00548_2004
crossref_primary_10_1161_01_RES_0000165800_81876_52
crossref_primary_10_3171_spi_2006_4_1_64
crossref_primary_10_1093_eurheartj_ehn134
crossref_primary_10_1016_j_neuropharm_2015_04_001
crossref_primary_10_1016_j_semcdb_2011_02_010
crossref_primary_10_1007_s11302_009_9140_8
crossref_primary_10_1007_s11302_011_9238_7
crossref_primary_10_3109_01480540903130690
crossref_primary_10_1021_cr0682195
crossref_primary_10_1016_j_yjmcc_2006_12_012
crossref_primary_10_1021_jm201292w
crossref_primary_10_1080_10739680590934736
crossref_primary_10_1536_ihj_49_707
crossref_primary_10_1080_15563650701397068
crossref_primary_10_1089_jcr_2010_0006
crossref_primary_10_1016_j_pharmthera_2013_06_002
crossref_primary_10_1016_j_bbrc_2005_09_176
crossref_primary_10_1111_j_1440_1681_2009_05228_x
crossref_primary_10_1161_01_HYP_0000144800_21037_a5
crossref_primary_10_1007_s11302_008_9097_z
crossref_primary_10_1007_s11302_024_10025_y
crossref_primary_10_1124_pr_113_008029
crossref_primary_10_1111_j_1540_8159_2005_00023_x
Cites_doi 10.1016/S0306-3623(98)00023-8
10.1016/0006-2952(94)90480-4
10.1007/BF00168545
10.1021/jm00047a018
10.1111/j.1476-5381.1995.tb14981.x
10.1113/jphysiol.1993.sp019927
10.1016/0014-2999(94)90604-1
10.1006/mvre.1997.2044
10.1152/ajpheart.2001.280.5.H2380
10.1038/sj.bjp.0704170
10.1016/S0306-3623(96)00466-1
10.1016/S0014-2999(01)00841-X
10.1111/j.1476-5381.1993.tb13586.x
10.1161/01.RES.85.7.634
10.1111/j.1476-5381.1990.tb15848.x
10.1046/j.1440-1681.1999.03054.x
10.1152/physrev.1990.70.3.761
10.1038/sj.bjp.0702462
10.2174/1381612802666221004174507
10.1038/sj.bjp.0701524
10.1111/j.1476-5381.1993.tb13522.x
10.1016/0014-2999(96)00200-2
10.2174/092986730203220223144628
10.1016/0014-2999(90)94197-6
ContentType Journal Article
Copyright 2003 Lippincott Williams & Wilkins, Inc.
2003 INIST-CNRS
Copyright_xml – notice: 2003 Lippincott Williams & Wilkins, Inc.
– notice: 2003 INIST-CNRS
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1097/00005344-200301000-00010
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1533-4023
EndPage 80
ExternalDocumentID 10_1097_00005344_200301000_00010
12500024
14467850
00005344-200301000-00010
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID -
.Z2
01R
08R
0R
1J1
3O-
40H
4Q1
4Q2
4Q3
53G
55
5GY
5RE
5VS
77Y
7O
7O~
8L-
AAMTA
AARTV
AAYEP
ABBUW
ABFLS
ABOCM
ABXVJ
ABZAD
ACDDN
ACEWG
ACGFS
ACWDW
ACWRI
ACXNZ
ADFPA
ADNKB
AE3
AENEX
AFFNX
AFUWQ
AHULI
AHVBC
AJIOK
AJNYG
AJYGW
ALMA_UNASSIGNED_HOLDINGS
AMJPA
ASCII
AWKKM
BQLVK
C45
CS3
DU5
DUNZO
E.X
EBS
EJD
EX3
F2K
F2L
F2M
F2N
F5P
FL-
FRP
FW0
GJ
H0
H0~
HZ
IN
IN~
JF9
JG8
JK3
JK8
K8S
KD2
KMI
L-C
N9A
N~7
N~B
N~M
O9-
OAG
OAH
OCUKA
ODA
OHASI
OK1
OL1
OLG
OLH
OLU
OLV
OLW
OLY
OLZ
OPUJH
ORVUJ
OUVQU
OVD
OVDNE
OWW
OWY
OXXIT
P-K
P2P
R58
RIG
RLZ
RSW
S4R
S4S
V2I
VH1
WOQ
WOW
X3V
X3W
X7M
Z2
ZGI
ZKB
ZXP
---
.-D
.55
.GJ
0R~
1CY
AAHPQ
AASOK
AAUGY
ABASU
ABDIG
ACCJW
ACGFO
ACILI
ADGGA
AE6
AEETU
AFDTB
AGINI
AHRYX
AI.
AJNWD
AKALU
ALMTX
AMKUR
AMNEI
AOHHW
BS7
DIWNM
EEVPB
FCALG
GNXGY
GQDEL
HZ~
IKREB
IPNFZ
IQODW
OJAPA
OPC
OWU
OWV
OWX
OWZ
T8P
TEORI
TSPGW
VVN
W3M
XXN
XYM
YFH
YOC
ZFV
ZZMQN
AAAAV
AAIQE
AASCR
ABJNI
ABVCZ
ACXJB
ADHPY
AHQNM
AINUH
AJZMW
CGR
CUY
CVF
ECM
EIF
HLJTE
NPM
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c4360-a73a8cc0dcbb6ab8890a35bfbd871c6608d073496569e24a5f3739d6b132cfec3
ISSN 0160-2446
IngestDate Fri Aug 16 23:42:09 EDT 2024
Fri Aug 23 01:56:09 EDT 2024
Sat Sep 28 08:37:02 EDT 2024
Sun Oct 22 16:02:41 EDT 2023
Thu Aug 13 19:45:21 EDT 2020
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Heart
Molecular form
Rat
Rodentia
Smooth muscle
In vitro
Biological activity
Vasodilation
Muscular relaxation
Vertebrata
Mammalia
Adenosine-Age-Coronary vessels-Rat heart-Receptors
Animal
Blood vessel
Myocardium
Circulatory system
Adenosine receptor
Mechanism of action
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c4360-a73a8cc0dcbb6ab8890a35bfbd871c6608d073496569e24a5f3739d6b132cfec3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://doi.org/10.1097/00005344-200301000-00010
PMID 12500024
PQID 72891899
PQPubID 23479
PageCount 8
ParticipantIDs proquest_miscellaneous_72891899
crossref_primary_10_1097_00005344_200301000_00010
pubmed_primary_12500024
pascalfrancis_primary_14467850
wolterskluwer_health_00005344-200301000-00010
ProviderPackageCode L-C
C45
7O~
AARTV
ADFPA
OLH
ASCII
OLG
ODA
ABZAD
ABBUW
JK3
ADNKB
JK8
H0~
1J1
OLV
8L-
OLU
JG8
OLW
OLZ
OLY
F2K
F2M
F2L
F2N
OHASI
AHVBC
AJNYG
FL-
KMI
K8S
AJIOK
OPUJH
V2I
S4R
S4S
4Q1
DUNZO
OAG
4Q2
OVDNE
4Q3
AMJPA
OAH
OVD
AHULI
ACEWG
.Z2
N~7
AWKKM
40H
N~B
OUVQU
ORVUJ
X3V
X3W
ACDDN
ACWRI
AAMTA
E.X
OWW
OCUKA
OWY
01R
ACXNZ
OL1
ABXVJ
IN~
KD2
OXXIT
77Y
ACWDW
JF9
FW0
PublicationCentury 2000
PublicationDate 2003-January
2003
2003-Jan
2003-01-00
20030101
PublicationDateYYYYMMDD 2003-01-01
PublicationDate_xml – month: 01
  year: 2003
  text: 2003-January
PublicationDecade 2000
PublicationPlace Philadelphia, PA
Hagerstown, MD
PublicationPlace_xml – name: Philadelphia, PA
– name: Hagerstown, MD
– name: United States
PublicationTitle Journal of cardiovascular pharmacology
PublicationTitleAlternate J Cardiovasc Pharmacol
PublicationYear 2003
Publisher Lippincott Williams & Wilkins, Inc
Lippincott
Publisher_xml – name: Lippincott Williams & Wilkins, Inc
– name: Lippincott
References Harden (R12-10-20110409) 1996; 307
Hein (R25-10-20110409) 1999; 291
Olsson (R2-10-20110409) 1990; 70
Linden (R8-10-20110409) 1994; 15
Fredholm (R9-10-20110409) 1994; 46
Feoktistov (R35-10-20110409) 1997; 49
Zhao (R7-10-20110409) 1997; 54
Conti (R18-10-20110409) 1993; 348
Hein (R26-10-20110409) 1999; 85
Rose'Meyer (R5-10-20110409) 1999; 32
Matherne (R14-10-20110409) 1990
Belardinelli (R23-10-20110409) 1998; 284
Mueller (R31-10-20110409) 1996; 2
Fozard (R32-10-20110409) 1993; 109
Lew (R24-10-20110409) 1999; 26
Fozard (R33-10-20110409) 1994; 252
Baraldi (R11-10-20110409) 1995; 2
Dart (R17-10-20110409) 1993; 471
Prentice (R21-10-20110409) 2001; 415
Merkel (R22-10-20110409) 1992; 260
Prentice (R34-10-20110409) 1997; 122
Kemp (R27-10-20110409) 1999; 126
Rubino (R6-10-20110409) 1995; 115
Collis (R10-10-20110409) 1993; 14
Flood (R13-10-20110409) 2001; 133
Moritoki (R15-10-20110409) 1990; 100
Morrison (R29-10-20110409) 2002; 282
Jacobson (R37-10-20110409) 1998; 19
Martin (R4-10-20110409) 1994; 270
Kim (R36-10-20110409) 1994; 37
Lewis (R3-10-20110409) 1997; 29
Stogall (R20-10-20110409) 1990; 190
Vials (R19-10-20110409) 1993; 109
Brackett (R28-10-20110409) 1994; 47
Hinschen (R16-10-20110409) 2001; 280
References_xml – volume: 291
  start-page: 655
  year: 1999
  ident: R25-10-20110409
  publication-title: J Pharmacol Exp Ther
  contributor:
    fullname: Hein
– volume: 32
  start-page: 35
  year: 1999
  ident: R5-10-20110409
  publication-title: Gen Pharmacol
  doi: 10.1016/S0306-3623(98)00023-8
  contributor:
    fullname: Rose'Meyer
– volume: 47
  start-page: 801
  year: 1994
  ident: R28-10-20110409
  publication-title: Biochem Pharmacol
  doi: 10.1016/0006-2952(94)90480-4
  contributor:
    fullname: Brackett
– volume: 46
  start-page: 143
  year: 1994
  ident: R9-10-20110409
  publication-title: Pharmacol Rev
  contributor:
    fullname: Fredholm
– volume: 15
  start-page: 298
  year: 1994
  ident: R8-10-20110409
  publication-title: TiPS
  contributor:
    fullname: Linden
– volume: 282
  start-page: H437
  year: 2002
  ident: R29-10-20110409
  publication-title: Am J Physiol
  contributor:
    fullname: Morrison
– volume: 348
  start-page: 108
  year: 1993
  ident: R18-10-20110409
  publication-title: Naunyn Schmiedebergs Arch Pharmacol
  doi: 10.1007/BF00168545
  contributor:
    fullname: Conti
– volume: 37
  start-page: 3614
  year: 1994
  ident: R36-10-20110409
  publication-title: J Med Chem
  doi: 10.1021/jm00047a018
  contributor:
    fullname: Kim
– volume: 115
  start-page: 648
  year: 1995
  ident: R6-10-20110409
  publication-title: Br J Pharmacol
  doi: 10.1111/j.1476-5381.1995.tb14981.x
  contributor:
    fullname: Rubino
– volume: 471
  start-page: 767
  year: 1993
  ident: R17-10-20110409
  publication-title: J Physiol
  doi: 10.1113/jphysiol.1993.sp019927
  contributor:
    fullname: Dart
– volume: 252
  start-page: R5
  year: 1994
  ident: R33-10-20110409
  publication-title: Eur J Pharmacol
  doi: 10.1016/0014-2999(94)90604-1
  contributor:
    fullname: Fozard
– volume: 54
  start-page: 243
  year: 1997
  ident: R7-10-20110409
  publication-title: Microvasc Res
  doi: 10.1006/mvre.1997.2044
  contributor:
    fullname: Zhao
– volume: 280
  start-page: H2380
  year: 2001
  ident: R16-10-20110409
  publication-title: Am J Physiol Heart Circ Physiol
  doi: 10.1152/ajpheart.2001.280.5.H2380
  contributor:
    fullname: Hinschen
– volume: 133
  start-page: 1063
  year: 2001
  ident: R13-10-20110409
  publication-title: Br J Pharmacol
  doi: 10.1038/sj.bjp.0704170
  contributor:
    fullname: Flood
– volume: 49
  start-page: 381
  year: 1997
  ident: R35-10-20110409
  publication-title: Pharmacol Rev
  contributor:
    fullname: Feoktistov
– volume: 29
  start-page: 421
  year: 1997
  ident: R3-10-20110409
  publication-title: Gen Pharmacol
  doi: 10.1016/S0306-3623(96)00466-1
  contributor:
    fullname: Lewis
– volume: 415
  start-page: 251
  year: 2001
  ident: R21-10-20110409
  publication-title: Eur J Pharmacol
  doi: 10.1016/S0014-2999(01)00841-X
  contributor:
    fullname: Prentice
– start-page: H1637
  year: 1990
  ident: R14-10-20110409
  publication-title: Am J Physiol
  contributor:
    fullname: Matherne
– volume: 109
  start-page: 424
  year: 1993
  ident: R19-10-20110409
  publication-title: Br J Pharmacol
  doi: 10.1111/j.1476-5381.1993.tb13586.x
  contributor:
    fullname: Vials
– volume: 85
  start-page: 634
  year: 1999
  ident: R26-10-20110409
  publication-title: Circ Res
  doi: 10.1161/01.RES.85.7.634
  contributor:
    fullname: Hein
– volume: 100
  start-page: 569
  year: 1990
  ident: R15-10-20110409
  publication-title: Br J Pharmacol
  doi: 10.1111/j.1476-5381.1990.tb15848.x
  contributor:
    fullname: Moritoki
– volume: 26
  start-page: 438
  year: 1999
  ident: R24-10-20110409
  publication-title: Clin Exp Pharm Physiol
  doi: 10.1046/j.1440-1681.1999.03054.x
  contributor:
    fullname: Lew
– volume: 14
  start-page: 360
  year: 1993
  ident: R10-10-20110409
  publication-title: TiPS
  contributor:
    fullname: Collis
– volume: 70
  start-page: 761
  year: 1990
  ident: R2-10-20110409
  publication-title: Physiol Rev
  doi: 10.1152/physrev.1990.70.3.761
  contributor:
    fullname: Olsson
– volume: 126
  start-page: 1796
  year: 1999
  ident: R27-10-20110409
  publication-title: Br J Pharmacol
  doi: 10.1038/sj.bjp.0702462
  contributor:
    fullname: Kemp
– volume: 270
  start-page: 893
  year: 1994
  ident: R4-10-20110409
  publication-title: J Pharmacol Exp Ther
  contributor:
    fullname: Martin
– volume: 2
  start-page: 501
  year: 1996
  ident: R31-10-20110409
  publication-title: Curr Pharmaceutical Des
  doi: 10.2174/1381612802666221004174507
  contributor:
    fullname: Mueller
– volume: 122
  start-page: 1509
  year: 1997
  ident: R34-10-20110409
  publication-title: Br J Pharmacol
  doi: 10.1038/sj.bjp.0701524
  contributor:
    fullname: Prentice
– volume: 284
  start-page: 1066
  year: 1998
  ident: R23-10-20110409
  publication-title: J Pharmacol Exp Ther
  contributor:
    fullname: Belardinelli
– volume: 19
  start-page: 184
  year: 1998
  ident: R37-10-20110409
  publication-title: TiPS
  contributor:
    fullname: Jacobson
– volume: 109
  start-page: 3
  year: 1993
  ident: R32-10-20110409
  publication-title: Br J Pharmacol
  doi: 10.1111/j.1476-5381.1993.tb13522.x
  contributor:
    fullname: Fozard
– volume: 307
  start-page: 44
  year: 1996
  ident: R12-10-20110409
  publication-title: Eur J Pharmacol
  doi: 10.1016/0014-2999(96)00200-2
  contributor:
    fullname: Harden
– volume: 260
  start-page: 437
  year: 1992
  ident: R22-10-20110409
  publication-title: J Pharmacol Exp Ther
  contributor:
    fullname: Merkel
– volume: 2
  start-page: 707
  year: 1995
  ident: R11-10-20110409
  publication-title: Curr Med Chem
  doi: 10.2174/092986730203220223144628
  contributor:
    fullname: Baraldi
– volume: 190
  start-page: 329
  year: 1990
  ident: R20-10-20110409
  publication-title: Eur J Pharmacol
  doi: 10.1016/0014-2999(90)94197-6
  contributor:
    fullname: Stogall
SSID ssj0014576
Score 1.9612042
Snippet Adenosine receptor-mediated coronary vasodilation was studied in isolated hearts from young (1–2 months) and mature (12–18 months) Wistar rats. The...
Adenosine receptor-mediated coronary vasodilation was studied in isolated hearts from young (1-2 months) and mature (12-18 months) Wistar rats. The...
SourceID proquest
crossref
pubmed
pascalfrancis
wolterskluwer
SourceType Aggregation Database
Index Database
Publisher
StartPage 73
SubjectTerms Adenosine - analogs & derivatives
Adenosine - pharmacology
Adenosine-5'-(N-ethylcarboxamide) - pharmacology
Adenosinic and purinergic receptors
Aging - physiology
Animals
Biological and medical sciences
Blood vessels and receptors
Cell receptors
Cell structures and functions
Coronary Vessels - drug effects
Fundamental and applied biological sciences. Psychology
Male
Molecular and cellular biology
Rats
Rats, Wistar
Receptors, Purinergic P1 - classification
Receptors, Purinergic P1 - drug effects
Vasodilation - drug effects
Vertebrates: cardiovascular system
Title Adenosine Receptor Subtypes Mediating Coronary Vasodilation in Rat Hearts
URI http://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00005344-200301000-00010
https://www.ncbi.nlm.nih.gov/pubmed/12500024
https://search.proquest.com/docview/72891899
Volume 41
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bi9NAFB5qF0QQ0fUWL-s86L64gWQm18faZmmRrcu2gj6FmckEFpekNK2y_94zmUwuUlEffAkldNo039cz55x85xyE3uZeILwwlDb8jzLby11iQwjm2yr_6LpBwAVVxcnzVbj8Es0SLxmNzGi17tx_RRrOAdaqcvYf0G4_FE7Aa8AcjoA6HP8K90mm2n8r3xFsmdxASP2-2nOVaa10mchOl9luy7oQ9zuryuxaC-Lq2ha2U87jVjd4OuC2iqGAddO1vm6T8_PFcjWdJ8tWMMm6ZOrVp1XyjoQXyddGglFW8ua26IY_z5PJ7Gox_Wh0wk0BmklM0C4l0baW6CcuA8cGV6Jpe22MLVXxK-1bY90Ga8A6bVr1xBOzSTsHzb9uK-zUFcaep3gB9qupnW_Us4OO27_shK0-UQXJYaRSQUcEDBgZo6PJ-Wz9oX0-5fn12ML2VzUaMdMO9NC3Dxyf-xuAid3kenjKoegG3vOjVIKJ6ltdL9HzetYP0YMGdzzRPHuERrI4RncvGkHGMTq91PjfnuF1V8lXneFTfNljxmO0aHmJDS-x4SVueYkNL3Gfl_i6wMBLrHn5BH0-T9bTud2M8bCFR-H-sJCySAgnE5wHjEdR7DDq85xnEKyLIHCiDPYZNbcgiCXxmJ_TkMZZwF1KRC4FfYrGRVnI5wg7wpXch-WxLz1f5jyMaM5iwgmRTsZCC7nmHqcb3a0l7aksalzSFpdaeOFY6GQARrewIYGF3hh0UrC96oEaK2S5r9KQRLEbxbGFnmnQurVEDRohnoXsAYqprm5Of0eSF3-6mJfoXi0nrZOAr9B4t93L1-hOle1PGo7-BCaOspM
link.rule.ids 315,782,786,4028,27932,27933,27934,64549,64569,65344,65364
linkProvider Ovid
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwvV1Lj9MwELagKwES4rG8ymPXB5TTBuXhOMmhhyjbpYW2qmiB5RTZjiOtkJKqSUH998w46XYrLQcunBpVnkjxzHg8r28IeV8wrlgYahv0KLdZ4Xo2uGCBjfFH1-VcKh-bk0eLcHYZnQ8RJmdXq4rNZ_XqA_6YYxofcBwO-oXLwaeFNRt-XwxKK12kgx_WPPk4NGFqLJKwzgfVr6Kxkpkpvwp8xlAEQIC75mlsxDri-H-PHCXpeDK-TjewwEyhQ7Q1G-wd70p-duiOt73rwI49XIkatrRoZ2HcdlmFNb8rzH_XP035-w0jdvH4P33-E_Kou-XSpBXLp-SOLo_JvWmXxz8m1rxFzN6e0eW-Aaw-oxad77G0t8_IOMkRzRyIKFxw9aqp1hTOOgwc13RqxoyA7aUp4jCI9ZZ-E3WVX7X1ffSqpF9EQ0egzE39nHy9GC7Tkd1Nf7AV84EPIvRFpJSTKym5kFEUO8IPZCFz8PEU506Uw_GEcPc81h4TQeGHfpxzCf61KrTyX5BeWZX6FaGOcrUMgDwONAt0IcPIL0TsSc_TTi7CPnF3vMxWLchHdiM5bzYzu95Mk693-uTkgOl7QpCfMApgwelOCjJQWczDiFJXmzoLwcl1wc_tk5etcOxpPZxP4bE-sQ-kJWubYrO_cfb1P64_JfdHy-kkm4xnn9-QB6ZA0YSV3pJes97od-RunW9OOjX5A9wCFYo
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwvV1Jb9NAFB5BK1VIqEBZGpZ2DsinGnkZbwcfLCchgdaKSFh6smbGY6lCsqPYAeXf897YaRqpHLhwSg7zfHjLvHnb9wh5XzJfsiBQJthRYbLSdkwIwTwT84-27ftCujicPJkH2Y9wOEKYnG0FH4fPmuUH_NHXNP7BdTgYFy7iT3MjnafxtZGNvs_jzJglH0c6TY1NEsZsOI43xjCuf5WtkWS6CctzGUNFADXuR6hxHOsQYazABA6TdHo5vS06ME_vokPMNRO8nt83_mwxHu_71p43e7zkDTC27DZi3PdkhTO_a6yCNz91E_wdVzZ-8l-Z8JQc9y9emnQq-ow8UNUJObrqa_onxJh16NmbC7rYDYM1F9Sgsx2u9uY5mSYFIpsDEYXHrlq29YrCvYdJ5IZe6ZUj4IdpipgMfLWh33hTFzddrx-9qegX3tIJGHbbvCBfx6NFOjH7TRCmZC5IgwcuD6W0CimEz0UYRhZ3PVGKAuI96ftWWMBVhdD3fqQcxr3SDdyo8AXE2rJU0n1JDqq6UqeEWtJWwgPyyFPMU6UIQrfkkSMcR1kFDwbE3ko0X3aAH_mdQr1mZn7LTF27twbkbE_0O0LQoiD04MD5VhdyMF-syfBK1esmDyDgtSHmHZBXnYrsaB3cVeGwATH3dCbvBmTzv0n29T-ePydHoDT55TT7_IY80r2KOsP0lhy0q7V6Rx42xfqst5U_PekYbA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Adenosine+receptor+subtypes+mediating+coronary+vasodilation+in+rat+hearts&rft.jtitle=Journal+of+cardiovascular+pharmacology&rft.au=HINSCHEN%2C+Andrea+K&rft.au=ROSE%27MEYER%2C+Roselyn+B&rft.au=HEADRICK%2C+John+P&rft.date=2003&rft.pub=Lippincott&rft.issn=0160-2446&rft.eissn=1533-4023&rft.volume=41&rft.issue=1&rft.spage=73&rft.epage=80&rft_id=info:doi/10.1097%2F00005344-200301000-00010&rft.externalDBID=n%2Fa&rft.externalDocID=14467850
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0160-2446&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0160-2446&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0160-2446&client=summon